Literature DB >> 8317951

A 24-year follow-up of California narcotics addicts.

Y I Hser1, D Anglin, K Powers.   

Abstract

OBJECTIVE: This study examined longitudinal patterns of narcotics use, other substance use, criminal involvement, morbidity, and mortality among narcotics addicts.
DESIGN: A 24-year follow-up study. Data were obtained from admission records and two face-to-face interviews conducted in 1974-1975 and 1985-1986. PARTICIPANTS: Five hundred eighty-one narcotics addicts admitted to the California Civil Addict Program during the years 1962 through 1964.
RESULTS: Most of this sample initiated narcotics use before age 20 years and had a mean age at program admission of 25.4 years. In 1974-1975, 13.8% of the sample died and 28.6% tested negative for opiates. Corresponding rates in 1985-1986 were 27.7% and 25.0%, respectively. Substance use and criminal involvement remained high among this sample into their late 40s. In any given year during the 10 years prior to the 1985-1986 interview, less than 10% of the sample participated in community-based treatment programs such as methadone maintenance. Disability, long periods of heavy alcohol use, heavy criminal involvement, and tobacco use were among the strongest correlates of mortality.
CONCLUSIONS: The results suggest that the eventual cessation of narcotics use is a very slow process, unlikely to occur for some addicts, especially if they have not ceased use by their late 30s.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8317951     DOI: 10.1001/archpsyc.1993.01820190079008

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  38 in total

Review 1.  Heroin maintenance for chronic heroin-dependent individuals.

Authors:  Marica Ferri; Marina Davoli; Carlo A Perucci
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

2.  How is tobacco treatment provided during drug treatment?

Authors:  Jamie J Hunt; A Paula Cupertino; Susan Garrett; Peter D Friedmann; Kimber P Richter
Journal:  J Subst Abuse Treat       Date:  2011-08-09

3.  Remission from drug abuse over a 25-year period: patterns of remission and treatment use.

Authors:  R K Price; N K Risk; E L Spitznagel
Journal:  Am J Public Health       Date:  2001-07       Impact factor: 9.308

4.  Understanding the drug treatment community's ambivalence towards tobacco use and treatment.

Authors:  Kimber P Richter; Jamie J Hunt; A Paula Cupertino; Susan Garrett; Peter D Friedmann
Journal:  Int J Drug Policy       Date:  2012-01-26

5.  Illicit drug use in heavy smokers with and without schizophrenia.

Authors:  Kristen M Mackowick; Stephen J Heishman; Heidi J Wehring; Fang Liu; Robert P McMahon; Deanna L Kelly
Journal:  Schizophr Res       Date:  2012-05-14       Impact factor: 4.939

6.  Health conditions among aging narcotics addicts: medical examination results.

Authors:  Yih-Ing Hser; Lillian Gelberg; Valerie Hoffman; Christine E Grella; William McCarthy; M Douglas Anglin
Journal:  J Behav Med       Date:  2004-12

7.  Long-term morbidity and mortality among a sample of cocaine-dependent black and white veterans.

Authors:  Joy C Yang; David Huang; Yih-Ing Hser
Journal:  J Urban Health       Date:  2006-09       Impact factor: 3.671

8.  Illicit drug use in young adults and subsequent decline in general health: the Coronary Artery Risk Development in Young Adults (CARDIA) Study.

Authors:  Stefan G Kertesz; Mark J Pletcher; Monika Safford; Jewell Halanych; Katharine Kirk; Joseph Schumacher; Stephen Sidney; Catarina I Kiefe
Journal:  Drug Alcohol Depend       Date:  2006-11-29       Impact factor: 4.492

9.  Course of recovery from alcoholism.

Authors:  Kamilla L Venner; Helen Matzger; Alyssa A Forcehimes; Rudolf H Moos; Sarah W Feldstein; Mark L Willenbring; Constance Weisner
Journal:  Alcohol Clin Exp Res       Date:  2006-06       Impact factor: 3.455

10.  Years of potential life lost among heroin addicts 33 years after treatment.

Authors:  Breda Smyth; Valerie Hoffman; Jing Fan; Yih-Ing Hser
Journal:  Prev Med       Date:  2007-02-08       Impact factor: 4.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.